LMAT vs MNKD: fair value comparison
LeMaitre Vascular, Inc. and MannKind Corporation · Updated 2026-09-12
Both currently screen as undervalued on TickrTrends' Forward Fair Value model. Within Healthcare, LMAT currently sits closer to the top of our discount ranking. LMAT carries the stronger quality grade.
| LMAT | MNKD | |
|---|---|---|
| Verdict | Undervalued | Undervalued |
| Last price | $81.08 | $3.98 |
| 12-month range | $79.54–$111.42 | $2.54–$6.01 |
| Sector rank | #23 of 113 Healthcare | #24 of 113 Healthcare |
| Quality grade | A | C |
| Leverage | Low | Low |
| Margin trend | Expanding | Stable |
| Revenue growth | Strong | High |
| RSI zone | Neutral | Neutral |
| 50/200-day trend | Downtrend | Mixed |
| DCF cross-check | Undervalued | Overvalued |
| 52-week position | The bottom quarter | The lower-middle quarter |
Full single-stock breakdowns: LMAT fair value analysis · MNKD fair value analysis